Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

盘前交易 07-20 07:55:42 EDT

37.08

+0.71

+1.95%

盘前37.38

+0.30+0.81%

07:51 EDT

最高37.63	最低35.29	成交量192.18万
今开35.79	昨收36.37	日振幅6.43%
总市值42.85亿	流通市值40.79亿	总股本1.16亿
成交额7,094万	换手率1.75%	流通股本1.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":37.08,"timestamp":1784318400000,"preClose":36.37,"halted":0,"volume":1921832,"hourTrading":{"tag":"盘前","latestPrice":37.3821,"preClose":37.08,"latestTime":"07:51 EDT","volume":2001,"amount":74636.809755,"timestamp":1784548301097,"change":0.3021,"changeRate":0.008147,"amplitude":0.03133},"delay":0,"changeRate":0.019521583722848526,"floatShares":110000000,"shares":115554295,"eps":-4.16,"marketStatus":"盘前交易","change":0.71,"latestTime":"07-20 07:55:42 EDT","open":35.79,"high":37.63,"low":35.29,"amount":70942625.601584,"amplitude":0.064339,"askPrice":37.41,"askSize":900,"bidPrice":37.11,"bidSize":21,"shortable":3,"etf":0,"ttmEps":-4.16,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784554200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1430280000000,"exchange":"NASDAQ","adjPreClose":37.08,"preHourTrading":{"tag":"盘前","latestPrice":37.3821,"preClose":37.08,"latestTime":"07:51 EDT","volume":2001,"amount":74636.809755,"timestamp":1784548301097,"change":0.3021,"changeRate":0.008147,"amplitude":0.03133},"postHourTrading":{"tag":"盘后","latestPrice":37.12,"preClose":37.08,"latestTime":"19:57 EDT","volume":234625,"amount":8699706.1587,"timestamp":1784332663536,"change":0.04,"changeRate":0.001079,"amplitude":0.008687},"volumeRatio":1.1631208565777826,"impliedVol":0.8614,"impliedVolPercentile":0.596},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"1131883109","title":"异动解读｜Viking Therapeutics盘中上涨8.68%，新型减肥药VK3019启动一期临床试验提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1131883109","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131883109?lang=zh_cn&edition=full","pubTime":"2026-07-08 03:35","pubTimestamp":1783452928,"startTime":"0","endTime":"0","summary":"7月8日，Viking Therapeutics盘中上涨8.68%，报42.07美元/股，成交额1.33亿美元。消息面上，公司近期宣布已启动在研减肥药VK3019的一期单剂量递增临床试验，此前该药已获得美国FDA的新药临床试验申请批准。VK3019为双重淀粉样蛋白和降钙素受体激动剂，该试验为随机、双盲、安慰剂对照研究，旨在评估BMI≥30健康成人中皮下注射VK3019的安全性、耐受性及疗效。多条管线持续推进叠加分析师平均目标价约94.62美元，支撑市场对公司减肥药布局的乐观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164828121","title":"Viking Therapeutics启动VK3019一期临床试验，评估新型淀粉样蛋白受体激动剂在健康成人中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164828121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164828121?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:06","pubTimestamp":1782299197,"startTime":"0","endTime":"0","summary":"Viking Therapeutics宣布，已启动一项一期临床研究，旨在评估其新型淀粉样蛋白受体激动剂VK3019在健康成年受试者中的表现。该研究标志着VK3019这一在研药物正式进入人体试验阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4585","BK4139","BK4599","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125765038","title":"Viking Therapeutics在2026年欧洲肥胖症大会上公布VK2735口服给药二期VENTURE试验13周数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1125765038","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125765038?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:06","pubTimestamp":1778583978,"startTime":"0","endTime":"0","summary":"Viking Therapeutics公司在2026年欧洲肥胖症大会上，公布了其候选药物VK2735口服给药二期VENTURE试验为期13周的研究数据。\n该试验旨在评估VK2735在肥胖或超重成人中的疗效与安全性。公布的数据涵盖了药物对患者体重、腰围及其他相关代谢指标的影响。\n研究结果显示，经过13周的治疗，接受VK2735治疗的患者在体重减轻方面取得了具有统计学意义的改善。此外，药物在试验中展现出了可接受的安全性特征。\n这些积极数据进一步支持了VK2735作为一种潜在的口服肥胖治疗方案的持续开发。公司计划基于这些结果，推进该药物的后续临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4599","VKTX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617635561","title":"顶尖药企竞相推出减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:16","pubTimestamp":1772806560,"startTime":"0","endTime":"0","summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AZN","BK4581","BK1583","BK4533","SG9999002224.SGD","LU0225771236.USD","NVO","VKTX","LU0868494617.USD","PFE","IE00BLSP4239.USD","LU1969619763.USD","BK1589","LU0306806265.USD","SG9999001176.SGD","000963","01801","SG9999003800.SGD","LU0170899867.USD","RHHBY","IE00B19Z3B42.SGD","LLY","BK1161","LU0289739699.SGD","LU1894683264.USD","LU0502904849.HKD","LU2328871848.SGD","BK4599","BK4534","LU0455707207.USD","LU2097828631.EUR","LU2097828714.EUR","LU0985481810.HKD","LU2488822045.USD","BK4568","BK4585","LU0225284248.USD","IE00B19Z3581.USD","LU0321505439.SGD","BK4550","SG9999001176.USD","LU1066053197.SGD","LU0122379950.USD","LU1066051498.USD","SG9999011175.SGD","IE000M9KFDE8.USD","IE00BBT3K403.USD","BK4007","LU0321505868.SGD","IE00BLSP4452.SGD","MRK","LU1894683348.USD","LU0058720904.USD","LU0234572021.USD","LU2097828474.EUR","SGXZ57979304.SGD","BK4592","LU2097828557.USD","LU2097828805.USD","HK0000165453.HKD","SG9999013999.USD","LU1023059063.AUD","LU0306807586.USD","BK4588","IE0002270589.USD","LU1883839398.USD","LU0456855351.SGD","LU2242644610.SGD","SG9999002232.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2610109927","title":"美股异动丨Viking Therapeutics大涨超15%，计划推进口服减肥药后期测试","url":"https://stock-news.laohu8.com/highlight/detail?id=2610109927","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610109927?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:46","pubTimestamp":1770907601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4550","VKTX","BK4539","BK4007","IWO","BK4535","BK4585","TWM","RWM","BK4534","IWN","TNA","MNQmain","BK4581","BK4139","BK4588","UWM","TZA","SRTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611115500","title":"Viking Therapeutics, Inc.股价飙升18.04% 市值涨6.87亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611115500","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611115500?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:31","pubTimestamp":1770906662,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时31分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨18.04%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Viking Therapeutics, Inc.、Lunai Bioworks Inc.、Tyra Biosciences, Inc.涨幅较大，Onconetix, Inc.、Quince Therapeutics, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为257.06%、76.25%、29.86%，振幅较大的相关个股有Cytomed Therapeutics Limited、Cue Biopharma, Inc.、Karyopharm Therapeutics Inc.，振幅分别为10.44%、9.33%、9.09%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223103a49ce736&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223103a49ce736&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4588","VKTX","BK4599","BK4007","BK4585","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610924388","title":"美股异动丨Viking Therapeutics盘前大涨超16%，公布口服减肥药后期测试计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2610924388","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610924388?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:47","pubTimestamp":1770904031,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SRTY","BK4588","BK4550","TWM","BK4585","TZA","BK4535","BK4539","BK4139","TNA","BK4534","IWN","BK4007","RWM","BK4581","MNQmain","VKTX","UWM","IWO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160970913","title":"盘前｜Fastly暴涨超40%，存储概念延续强势，思科、APP、QS下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1160970913","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160970913?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:26","pubTimestamp":1770899186,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前时段小幅走高。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDK","VKTX","FSLY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1170964209","title":"Viking Therapeutics盘前股价飙升11.7%，公司计划推进口服减肥药进入后期试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1170964209","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170964209?lang=zh_cn&edition=full","pubTime":"2026-02-12 18:14","pubTimestamp":1770891260,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc. (VKTX) 股价在盘前交易时段大幅上涨11.7%，此前该公司宣布计划将其口服肥胖症治疗药物推进至后期试验阶段。这一积极的市场反应凸显了投资者对该公司在代谢疾病治疗领域研发进展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VKTX","BK4588","BK4585","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132543371","title":"盘前异动｜Fastly暴涨近40%，存储概念延续强势，思科绩后跌近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132543371","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132543371?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:15","pubTimestamp":1770887757,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前时段小幅走高。","market":"us","thumbnail":"https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSLY","VKTX","SNDK"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1171356215","title":"异动解读 | Viking Therapeutics盘前大涨12.26%，因计划推进口服肥胖症药物后期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1171356215","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171356215?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:15","pubTimestamp":1770887731,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.今日盘前股价大涨12.26%，引起了市场的高度关注。消息面上，公司宣布计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段。公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的一个重要因素，因为目前还没有其他双效或三效激动剂同时提供这两种剂型。中期研究数据显示，VK2735口服片剂每日一次，在13周后帮助患者平均体重下降达12.2%。此外，公司表示其充足的现金储备将支持VK2735的后期研究顺利完成。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118244840","title":"异动解读 | Viking Therapeutics夜盘大涨9.91%，因计划推进口服肥胖症药物后期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1118244840","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118244840?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:06","pubTimestamp":1770858369,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.（VKTX）在今日夜盘交易中股价大涨9.91%，引起了市场的广泛关注。消息面上，公司宣布计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段。公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的重要优势，因为目前尚无其他同类药物同时提供这两种剂型。中期研究数据显示，VK2735口服片剂每日一次，在13周后帮助患者平均体重下降达12.2%。这一进展被视为公司在肥胖症治疗领域的重要里程碑，增强了投资者对其药物商业化前景和未来增长潜力的信心，从而推动了股价在夜盘时段的显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142794644","title":"异动解读 | Viking Therapeutics盘后大涨10.40%，因计划推进口服肥胖症药物后期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1142794644","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142794644?lang=zh_cn&edition=full","pubTime":"2026-02-12 06:08","pubTimestamp":1770847717,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc.（VKTX）今日盘后股价大涨10.40%，引起了市场的高度关注。消息面上，公司宣布计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段。公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的一个重要因素，因为目前还没有其他双效或三效激动剂同时提供这两种剂型。后期研究结果表明，VK2735口服片剂每日一次，13周后体重平均下降达12.2%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605323537","title":"Viking Therapeutics, Inc.盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605323537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605323537?lang=zh_cn&edition=full","pubTime":"2026-01-24 04:30","pubTimestamp":1769200210,"startTime":"0","endTime":"0","summary":"北京时间2026年01月24日04时30分，Viking Therapeutics, Inc.股票出现波动，股价快速下跌5.00%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124043011a44f7ec4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124043011a44f7ec4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VKTX","BK4139","BK4007","LENZ","BK4585","BK4599","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517619311","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅上涨5.01%报29.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517619311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517619311?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:09","pubTimestamp":1741273775,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时09分，Viking Therapeutics, Inc.股票出现波动，股价大幅上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1475.89%、720.61%、73.18%，振幅较大的相关个股有Moolec Science Sa C/Wts 、Aeon Biopharma, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 ，振幅分别为44.44%、42.11%、39.20%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VKTX","BK4599","BK4585","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516263769","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516263769","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516263769?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:52","pubTimestamp":1741013569,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时52分，Viking Therapeutics, Inc.股票出现异动，股价急速下挫5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、木薯科学涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为687.62%、115.08%、86.65%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、40.78%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VKTX","BK4585","LENZ","BK4599","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514038900","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514038900?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:23","pubTimestamp":1740669804,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时23分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.14%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为884.66%、177.60%、104.83%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为74.16%、43.51%、34.80%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4599","BK4139","LENZ","VKTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514017433","title":"现金9亿美金\"子弹充足\"！Viking能否复制礼来神话？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514017433","media":"美港股观察社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514017433?lang=zh_cn&edition=full","pubTime":"2025-02-25 18:00","pubTimestamp":1740477639,"startTime":"0","endTime":"0","summary":"VK2735口服开发进展在2024年4月，Viking Therapeutics报告了口服VK2735治疗肥胖受试者4周的数据，但剂量最高仅为40毫克。2024年11月，Viking Therapeutics在ObesityWeek上展示了这些额外的结果，并指出接受100毫克VK2735治疗的9名患者中仅出现轻度恶心。财务概况截至2024年底，Viking Therapeutics拥有9.03亿美元的现金、现金等价物和短期投资。公司报告该季度净亏损为3540万美元。Viking Therapeutics尚未提交10-K年报。然而，2025年2月的公司文件提供的财务摘要显示，流通股为1.116亿股，使Viking Therapeutics的市值达到38亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226015322abdcae97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226015322abdcae97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1868836914.USD","SGXZ99366536.SGD","LU2324357040.USD","IE00BK4W5L77.USD","LU2461242641.AUD","LU2237443549.SGD","LU0256863811.USD","LU2106854487.HKD","LU2264538146.SGD","LU1988902786.USD","LU2468319806.SGD","SG9999015978.USD","LU1551013342.USD","LU1983299246.USD","LU2237443895.HKD","LU2237443978.SGD","SG9999015952.SGD","LLY","LU0114720955.EUR","SG9999015945.SGD","IE00BK4W5M84.HKD","IE0002141913.USD","LU2602419157.SGD","LU1280957306.USD","LU0203201768.USD","LU2491049909.HKD","VKTX","LU0417517546.SGD","SG9999014880.SGD","LU0820561818.USD","LU0109391861.USD","LU1267930730.SGD","LU1720051017.SGD","IE00BFTCPJ56.SGD","LU1548497426.USD","SGXZ51526630.SGD","LU2361044865.SGD","IE00B4R5TH58.HKD","LU1868837136.USD","LU1057294990.SGD","BK4534","LU2491050071.SGD","LU1291159041.SGD","LU1974910355.USD","LU1069344957.HKD","LU0106261372.USD","LU2491050154.USD","LU0058720904.USD","LU1868837300.USD","BK4588","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2513727908","title":"Viking Therapeutics, Inc.盘中异动 早盘急速下跌5.20%报32.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513727908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513727908?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:32","pubTimestamp":1740407523,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时32分，Viking Therapeutics, Inc.股票出现异动，股价快速下挫5.20%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223203abdb0df3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223203abdb0df3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VKTX","BK4139","LENZ","BK4585","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513218261","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513218261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513218261?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:23","pubTimestamp":1740158624,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时23分，Viking Therapeutics, Inc.股票出现波动，股价快速拉升5.22%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012345988e0421&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012345988e0421&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","BK4588","BK4139","BK4599","VKTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0458},{"period":"1month","weight":0.2242},{"period":"3month","weight":0.0534},{"period":"6month","weight":0.0932},{"period":"1year","weight":0.1562},{"period":"ytd","weight":0.054}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1835},{"period":"ytd","weight":0.09}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006749},{"month":2,"riseRate":0.545455,"avgChangeRate":0.220725},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.034739},{"month":4,"riseRate":0.454545,"avgChangeRate":0.013541},{"month":5,"riseRate":0.333333,"avgChangeRate":0.076833},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.004304},{"month":7,"riseRate":0.5,"avgChangeRate":0.010737},{"month":8,"riseRate":0.454545,"avgChangeRate":0.012248},{"month":9,"riseRate":0.272727,"avgChangeRate":0.053956},{"month":10,"riseRate":0.363636,"avgChangeRate":0.052351},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.018186},{"month":12,"riseRate":0.545455,"avgChangeRate":0.143438}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}